<SEC-DOCUMENT>0001171520-22-000424.txt : 20220722
<SEC-HEADER>0001171520-22-000424.hdr.sgml : 20220722
<ACCEPTANCE-DATETIME>20220722141843
ACCESSION NUMBER:		0001171520-22-000424
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20220722
DATE AS OF CHANGE:		20220722

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		221099639

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SINGER JULIAN D.
		CENTRAL INDEX KEY:			0001628706

	FILING VALUES:
		FORM TYPE:		DFAN14A

	MAIL ADDRESS:	
		STREET 1:		2200 FLETCHER AVENUE
		STREET 2:		SUITE 501
		CITY:			FORT LEE
		STATE:			NJ
		ZIP:			07024
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>eps10374.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 13.5pt Arial,sans-serif; margin: 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 13.5pt Arial,sans-serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 8pt Arial,sans-serif; margin: 0">&nbsp;</P>

<P STYLE="font: 16pt Arial,sans-serif; margin: 0; text-align: center"><B>SCHEDULE 14A </B></P>

<P STYLE="font: 6pt Arial,sans-serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of the </B></P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt"><FONT STYLE="font-family: Arial,sans-serif">Filed by the Registrant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0 0 2pt"><FONT STYLE="font-family: Arial,sans-serif">Filed by a Party other than the
Registrant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: MS Gothic">&#9745;</FONT></P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0 0 2pt">Check the appropriate box:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD><TD><FONT STYLE="font-family: Arial,sans-serif">Preliminary Proxy Statement </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD><TD><FONT STYLE="font-family: Arial,sans-serif">Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD><TD><FONT STYLE="font-family: Arial,sans-serif">Definitive Proxy Statement </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9745;</FONT></TD><TD><FONT STYLE="font-family: Arial,sans-serif">Definitive Additional Materials </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman,serif; margin-top: 0; margin-bottom: 2pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD><TD><FONT STYLE="font-family: Arial,sans-serif">Soliciting Material Pursuant to &sect;240.14a-12</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>CATALYST BIOSCIENCES, INC</B></FONT><B>.</B></P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: center"><B>(Name of Registrant as Specified in Its Charter)</B></P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Arial,sans-serif; margin: 0; text-align: center"><B>JDS1, LLC</B></P>

<P STYLE="font: 14pt Arial,sans-serif; margin: 0; text-align: center"><B>CCUR HOLDINGS, INC.</B></P>

<P STYLE="font: 14pt Arial,sans-serif; margin: 0; text-align: center"><B>CIDM II, LLC</B></P>

<P STYLE="font: 14pt Arial,sans-serif; margin: 0; text-align: center"><B>JULIAN D. SINGER</B></P>

<P STYLE="font: 14pt Arial,sans-serif; margin: 0; text-align: center"><B>DAVID S. OROS</B></P>

<P STYLE="font: 14pt Arial,sans-serif; margin: 0; text-align: center"><B>SHELLY C. LOMBARD</B></P>

<P STYLE="font: 14pt Arial,sans-serif; margin: 0; text-align: center"><B>MATTHEW STECKER</B></P>

<P STYLE="font: 14pt Arial,sans-serif; margin: 0; text-align: center"><B>IGOR VOLSHTEYN</B></P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement, if Other Than the
Registrant)</B></P>

<P STYLE="font: 10pt Arial,sans-serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0">Payment of Filing Fee (Check the appropriate box):</P>

<P STYLE="font: 12pt Arial,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman,serif; width: 4%"><FONT STYLE="font-family: MS Gothic">&#9745;</FONT></TD>
    <TD STYLE="width: 96%">
    <P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: justify">No fee required</P>
    <P STYLE="font: 12pt Arial,sans-serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman,serif"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD>
    <TD>
    <P STYLE="font: 12pt Arial,sans-serif; margin: 0">Fee paid previously with preliminary materials</P>
    <P STYLE="font: 12pt Arial,sans-serif; margin: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman,serif"><FONT STYLE="font-family: MS Gothic">&#9744;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman,serif"><FONT STYLE="font-family: Arial,sans-serif">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Arial,sans-serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial,sans-serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial,sans-serif; margin: 0 0 12pt; text-align: justify">This Schedule 14A is being filed by JDS1, LLC, a Delaware
limited liability company (&ldquo;<U>JDS1</U>&rdquo;), CCUR Holdings, Inc., a Delaware corporation (&ldquo;<U>CCUR</U>&rdquo;), CIDM II,
LLC, a Delaware limited liability company (&ldquo;<U>CIDM II</U>&rdquo;), Julian D. Singer, David S. Oros, Shelly C. Lombard, Matthew
Stecker, and Igor Volshteyn (collectively, the &ldquo;<U>JDS1 Group</U>&rdquo;).</P>

<P STYLE="font: 11pt Arial,sans-serif; margin: 0 0 12pt; text-align: justify"><B>Schedule 13D Amendment No. 15 Filed on July 22, 2022</B></P>

<P STYLE="font: 11pt Arial,sans-serif; margin: 0 0 12pt; text-align: justify">On July 22, 2022, the JDS1 Group filed with the Securities
and Exchange Commission (&ldquo;<U>SEC</U>&rdquo;) Amendment No. 15 to its Schedule 13D (the &ldquo;<U>Schedule 13D/A</U>&rdquo;) with
respect to Catalyst Biosciences, Inc., a Delaware Corporation (the &ldquo;<U>Company</U>&rdquo; or the &ldquo;<U>Issuer</U>&rdquo;). The
following disclosure was included in Item 4 of the Schedule 13D/A and is being included in this Schedule 14A because such disclosure may
be deemed&nbsp;to be solicitation material in connection with the JDS1 Group&rsquo;s plans to solicit proxies from the Company&rsquo;s
stockholders in connection with the Company&rsquo;s 2022 Annual Meeting of Stockholders scheduled to be held in person on August 15, 2022
(the &ldquo;<U>2022 Annual Meeting</U>&rdquo;).</P>

<P STYLE="font: 11pt Arial,sans-serif; margin: 0 0 12pt; text-align: justify"><I>&ldquo;</I>Item 4 is hereby amended to add the following:</P>

<P STYLE="font: 11pt Arial,sans-serif; margin: 0 0 12pt; text-align: justify">On July 19, 2022, JDS1 and the other Reporting Persons filed
with the SEC their definitive proxy statement (the &ldquo;<U>JDS1 Proxy Statement</U>&rdquo;) and accompanying definitive <B><U>GOLD</U></B>
proxy card in connection with their solicitation of proxies to elect three nominees, Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn,
to the Company&rsquo;s Board of Directors at the Company&rsquo;s 2022 Annual Meeting of Stockholders scheduled to be held in person on
August 15, 2022 (the &ldquo;<U>2022 Annual Meeting</U>&rdquo;).</P>

<P STYLE="font: 11pt Arial,sans-serif; margin: 0 0 12pt; text-align: justify">On July 21, 2022, JDS1 began mailing to the Company&rsquo;s
stockholders the JDS1 Proxy Statement and the accompanying definitive <B><U>GOLD</U></B> proxy card. On July 21, 2022, JDS1 also began
mailing, together with the JDS1 Proxy Statement, a letter to stockholders.</P>

<P STYLE="font: 11pt Arial,sans-serif; margin: 0 0 12pt; text-align: justify">On July 21, 2022, in accordance with the Company&rsquo;s
Bylaws, JDS1 delivered to the Company an update and supplement to the advance notice of nominations and other proposed business that it
previously submitted to the Company on March 4, 2022, as subsequently updated and supplemented on April 20, 2022 and June 16, 2022.&nbsp;</P>

<P STYLE="font: 11pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-left: 0">As disclosed in the JDS1 Proxy Statement,
representatives of JDS1 engaged in settlement discussions with representatives of the Company on July 15, 2022. As also disclosed in the
JDS1 Proxy Statement, such discussions did not result in a consensus being reached as to a settlement framework. Based on the premise
that there was no viable path forward for JDS1 to reach a settlement with the Company that would avoid a proxy contest at the 2022 Annual
Meeting, and taking into consideration that, on July 19, 2022, the Company filed with the SEC its definitive proxy statement for the 2022
Annual Meeting and issued a &ldquo;fight letter&rdquo; to stockholders that the Company also filed with the SEC on July 19, 2022, JDS1
filed the JDS1 Proxy Statement with the SEC later in the day on July 19, 2022.</P>

<P STYLE="font: 11pt Arial,sans-serif; margin: 0 0 12pt; text-align: justify">On July 21, 2022, at the suggestion of another large stockholder
of the Company, a representative of JDS1 telephoned a representative of the Company to further see if there was a possibility of restarting
settlement discussions and to discuss a settlement framework, which included, among other terms, a commitment from the Company as to the
amount of a cash distribution to stockholders within a fixed period of time. While such discussions did not result in any consensus being
reached at such time as to a settlement framework, JDS1 anticipates having further discussions with the Company. JDS1 is unable to predict
whether any future discussions with the Company will result in any settlement being reached that will avoid a proxy contest at the 2022
Annual Meeting. Accordingly, until such time, if any, that a settlement is reached with the Company, JDS1 is continuing to move forward
with its proxy contest for the 2022 Annual Meeting.</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial,sans-serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Arial,sans-serif; margin: 0 0 12pt; text-align: justify">Except as set forth in the Schedule 13D or such as would
occur upon or in connection with completion of, or following, any of the actions discussed in the Schedule 13D, no Reporting Person has
any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule
13D. The Reporting Persons intend to review their investment in the Company on a continuing basis. Depending on various factors including,
without limitation, the Company&rsquo;s financial position and strategic direction, actions taken by the Board, the price levels of the
Shares, other investment opportunities available to the Reporting Persons, conditions in the securities markets and general economic and
industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Company as they
deem appropriate including, without limitation, engaging in communications with management and/or the Board, engaging in communications
with one or more stockholders of the Company and others about the Company and the Reporting Persons&rsquo; investment, making suggestions
and/or proposals concerning the Company&rsquo;s capitalization, uses of its cash, including the distribution of cash to the Company&rsquo;s
stockholders, ownership structure, operations, prospects, business and financial strategies, strategic transactions, assets and liabilities,
business and financing alternatives, opportunities to unlock shareholder value, the structure and composition of the Board, and such other
matters as the Reporting Persons may deem relevant to their investment in the Company, selling some or all of their Shares in the open
market or otherwise, engaging in short selling of or any hedging or similar transaction with respect to the Shares, acquiring additional
Shares and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value
of securities of the Company, or changing their intention with respect to any and all matters referred to in Item 4.&rdquo;</P>

<P STYLE="font: 11pt Arial,sans-serif; margin: 0 0 12pt; background-color: white"><B>Additional Information and Where to Find It</B></P>

<P STYLE="font: 11pt Arial,sans-serif; margin: 0 0 12pt; text-align: justify; background-color: white">On July 19, 2022, the JDS1 Group
filed a definitive proxy statement and an accompanying definitive <B><U>GOLD</U></B> proxy card with the SEC to be used to solicit proxies
from the Company&rsquo;s stockholders in connection with the 2022 Annual Meeting. <B>BEFORE MAKING ANY VOTING DECISION, INVESTORS AND
STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ JDS1&rsquo;S PROXY STATEMENT, THE ACCOMPANYING <U>GOLD</U> PROXY CARD, AND ANY AMENDMENTS
AND SUPPLEMENTS THERETO, AND OTHER DOCUMENTS FILED BY JDS1 WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS
THEY WILL CONTAIN IMPORTANT INFORMATION.</B> Information regarding the identity of participants, and their direct or indirect interests,
by security holdings or otherwise, is set forth in JDS1&rsquo;s Proxy Statement, including the schedules thereto. Stockholders can obtain
JDS1&rsquo;s Proxy Statement, any amendments or supplements to JDS1&rsquo;s Proxy Statement and other documents filed by JDS1 with the
SEC for no charge at the SEC&rsquo;s website at www.sec.gov. Copies will also be available at no charge at the following website: http://www.myproxyonline.com/jds1.
Investors can also contact JDS1&rsquo;s proxy solicitor, Kingsdale Advisors, toll free at 1-888-302-5677.</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
